



MMHCC Newsletter November 2006

MouseLine

Mouse Strain With Gene Stutter Will Help Leukemia Research

Cancer researchers have developed a new strain of mice that should help reveal how an unusual change in a certain gene contributes to a particularly deadly form of acute myeloid leukemia (AML).

A study of the strain by its developers at the Ohio State University Comprehensive Cancer Center (OSUCCC) suggests that the genetic change comes early in the disease, and that it over-activates a second gene that helps govern blood cell development.

The genetic change, known as a partial tandem duplication, is located in a gene called MLL (for mixed-lineage leukemia). A partial tandem duplication is a type of gene mutation that occurs when a section of a gene is repeated, like a stutter in the gene's DNA.



The new mouse model should help leukemia researchers to learn how this mutation contributes to AML development, and it may lead to new ways to treat, diagnose and perhaps prevent the disease.

The findings were published online Sept. 14 in the *Journal of Clinical Investigation*.

"When leukemia strikes, it's like a hurricane arriving without an advance weather forecast – you have no information about how it got there, and it's a level-5 storm," says Michael A. Caligiuri, principal investigator of the study and director of the OSUCCC.

"Studying live models like this mouse strain helps us begin to understand the earliest events in the development of leukemia. This in turn will someday allow us to understand what causes leukemia in people, predict who is at greatest risk and prevent leukemia from ever developing in those patients."

Genes store information for a protein. Mutations can alter the protein, perhaps making it function differently. In this case, the duplication within the MLL gene contributes to an aggressive form of AML. This new study begins to reveal how it does so.

AML will strike an estimated 10,000 Americans this year, and about 45 percent of those will have cancer cells with normal-looking chromosomes. Some 4-7 percent of patients in this group will have cancer cells with this mutation. Their disease is likely to respond poorly to therapy and their remissions will be short. Several years ago, Caligiuri, together with OSUCCC researchers Clara D. Bloomfield and Carlo M. Croce, discovered this mutation in the MLL gene. The MLL gene stores information for a protein that helps regulate the activity of other genes called Hox (for homeobox) genes, which control many aspects of development.

To make the mouse strain, Caligiuri and his colleagues used genetic engineering techniques to remove a section of the normal MLL gene from one animal and insert it into the MLL gene of another. The result is a strain of mice with a mutation that mimics the one that occurs in human leukemia.





The researchers then looked to see how the mutation affected the animals. The most obvious change was a missing or rudimentary 13th rib and an additional vertebra in the lower backbone. This suggested the mutation was affecting Hox genes, some of which govern the growth and development of the skeleton and of blood cells.

Next, the researchers examined cells in the bone marrow and spleen that give rise to blood cells. The cells looked normal, as did their numbers. But when the cells were grown in a laboratory test tube, those with the mutation grew far faster and formed much larger colonies than control cells without the mutation.

In addition, cells with the mutation could be used to start new colonies four or more times, while control cells could not. This showed that cells with the mutation lived longer than normal.

Rapid proliferation and unusually long life are features of cancer cells.

Three Hox genes could be involved in the increased proliferation of the progenitor cells. An analysis showed that of the three, the HoxA9 gene was overactive. Its protein was being made at levels much higher than normal.

Furthermore, the researchers also discovered changes that might explain why the gene is overactive. For example, they found that proteins called histones, which help control a gene's activity, were being altered.

"We show that the histones are being modified in ways that can increase the activity of the HoxA9 gene," says first author Adrienne M. Dorrance, a graduate student in Caligiuri's laboratory and the recipient of the Lady Tata Memorial Trust Award for her work on this gene. "We believe that the mutation is somehow activating this modification."

In spite of these changes, the mouse strain does not develop leukemia.

"The failure of the mice to develop leukemia suggests that the partial tandem duplication occurs early in the leukemic process and that additional mutations are needed for the disease to occur," Dorrance says. "That's what we're now focused on."

"Ultimately," Caligiuri says, "we believe that this mouse will further our understanding of how leukemia develops and open up new therapeutic options for this group of AML patients with a poor prognosis." Funding from Lady Tata Memorial Trust Award and the National Cancer Institute supported this research.

Source:

ScienceDaily, <http://www.sciencedaily.com/releases/2006/09/060919230138.htm>

Publication:

Dorrance AM, Liu S, Yuan W, Becknell B, Arnoczky KJ, Guimond M, Strout MP, Feng L, Nakamura T, Yu L, Rush LJ, Weinstein M, Leone G, Wu L, Ferketich A, Whitman SP, Marcucci G, Caligiuri MA.

Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. J Clin Invest. 2006 Oct;116(10):2707-16. Epub 2006 Sep 14.

PMID: 16981007





Selected Meetings

December 6 - 9, 2006

AACR Special Conference: Innovations in Prostate Cancer Research

San Francisco, California

Meeting information: <http://www.aacr.org/default.aspx?p=6526>

December 9 - 12, 2006

The American Society of Hematology - 48th Annual Meeting and Exposition

Orlando, Florida

Meeting information: <http://www.hematology.org/meetings/2006/index.cfm>

January 21 - 25, 2007

In the Forefront of Basic and Translational Cancer Research - AACR/JCA 7th Joint Conference

Waikoloa, Hawaii

Meeting information: <http://www.aacr.org/default.aspx?p=7003>

Advance registration, Abstract submission and Awards deadline: November 17, 2006

February 5 - 7, 2007

caBIGTM Annual Meeting

Washington, D.C.

Meeting information: <https://cabig.nci.nih.gov/2007caBIGconference/>

Announcements and Funding Opportunities

Announcing Electronic Grant Submission Training Opportunity

NOT-OD-07-009

National Institutes of Health

<http://grants.nih.gov/grants/guide/notice-files/NOT-OD-07-009.html>

Request for Information (RFI): To Solicit Input and Ideas for Roadmap Trans-NIH Strategic Initiatives

NOT-OD-07-011

National Institutes of Health

<http://grants.nih.gov/grants/guide/notice-files/NOT-OD-07-011.html>





Announcements and Funding Opportunities cont.

Notice on Roadmap Trans-NIH Strategic Initiatives Idea Input and Nomination Process

NOT-RM-06-018

National Institutes of Health

<http://grants.nih.gov/grants/guide/notice-files/NOT-RM-06-018.html>

Announcement of the NCI Early Detection Research Network (EDRN) Program for Rapid, Independent Diagnostic Evaluation (PRIDE) for Cancer Biomarkers

NOT-CA-07-003

National Cancer Institute

<http://grants.nih.gov/grants/guide/notice-files/NOT-CA-07-003.html>

Corrections to RFA-RR-06-005, Knockout Mouse Project (KOMP) Repository

NOT-RR-07-001

National Center for Research Resources

<http://grants.nih.gov/grants/guide/notice-files/NOT-RR-07-001.html>

Membrane Associated Signaling Defects in Immune Cells with Aging

RFA-AG-07-006

National Institute on Aging

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-07-006.html>

Bioinformatics

caBIG™ Annual Meeting 2007

The goal of the caBIG™ initiative is to provide an informatics infrastructure or "grid" that accelerates clinical and basic research and supports collaborative work across the cancer and biomedical research communities. The infrastructure and tools of caBIG™ are also widely applicable beyond the cancer community.

The 2007 annual meeting will feature scientific presentations, technology demonstrations, and interactive sessions for real-time contributions to caBIG™ activities. For newcomers, there will be a full day of introductory sessions before the meeting and additional sessions throughout.

The meeting will be held on February 5 - 7, 2007, at the Marriott Wardman Park Hotel in Washington, D.C. For additional information and registration please visit

<https://cabig.nci.nih.gov/2007caBIGconference/>





MMHCC
*the Mouse Models
of Human Cancers Consortium*

Disclaimer

NCI does not endorse or recommend any commercial products, processes, or services described in this newsletter, or in any "off-site" external link web pages referenced in this newsletter or in the NCI emice website. The views and opinions of authors expressed in this newsletter do not necessarily state or reflect those of the United States Government and they may not be used for advertising or product endorsement purposes. Further, this newsletter is intended for informational purposes only. NCI does not warrant or assume any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed. NCI makes no warranties, either express or implied; including the warranties of merchantability or fitness for a particular purpose or that the use of this software or data will not infringe any third party patents, copyrights, trademark, or other rights.



To unsubscribe from this newsletter please send an email to Dr. Betty Tarnowski
tarnowsb@mail.nih.gov Send meeting announcements and other information you would like to
have included in this newsletter to Ulli Wagner: ulrike@mail.nih.gov

